Orion Biotechnology Poland

A wholly owned subsidiary of
Orion Biotechnology
Canada Ltd.



Focused on oncology and microbicide R&D as well as pharmaceutical trial management.



Headquartered in Cracow, Poland at the Jagiellonian Centre of Innovation. Orion Biotechnology Poland has ready access to some of Europe’s top talent in pharmacology and biotechnology research.

Sylwia Skrzyńska, PhDBeata Binięda
Sylwia Skrzyńska, PhD
Pre-Clinical Research Consultant

Ms. Skrzyńska is the Pre-Clinical Research Consultant at Orion Biotechnology.  She has over 10 years experience in pre-clinical as well as clinical studies, in many fields including: oncology, immunology, neurology, and metabolic diseases. Sylwia has created and conducted numerous pre-clinical studies at Mossakowski Medical Research Centre in the Polish Academy of Sciences. She has also been a lecturer at Medical University at Warsaw and presenter at many Polish and international conferences. Sylwia is the author and co-author of many publications.  Ms. Skrzynska has also worked in Clinical Research Organizations (CROs) as a Clinical Research Associate.

Beata Binięda
Senior Programme Administrator

Mrs Binięda is the Senior Programme Administrator at Orion Biotechnology Poland, where she is responsible for all administrative activity with the business, including financial control of research projects financed through public sources such as those from the National Centre for Research and Development. Beata has extensive experience in accounting for research projects that are co-financed by the National Science Centre and the Foundation for Polish Science. In the past she has held senior administrative positions at the Malopolska Centre of Biotechnology, Jagiellonian University. Mrs Binieda was also previously involved with the SPIN project – Malopolska Center of Knowledge Transfer.



ORION Poland is performing research and development under the Operational Programme – Smart Growth 2014-2020.

Project title:  Development of a new candidate microbicide for the prevention of HIV transmission

The aim of the Project is to develop an innovative microbicide drug candidate that is used in the prevention of sexually transmitted infections (STIs) – in particular in the prevention of HIV – a lifestyle disease – and potentially HPV causing cervical cancer and HSV-2.

Application for project co-funding within European Union, European Regional Development Fund:

  • Total project amount:  9,928,239.50 PLN
  • Co-funding portion:  7,034,900.75 PLN


Project title:  CCR5 Immunotherapy for Advanced Cancer

The project will develop a product innovation – the first in its class (first-in-class) drug candidate for use in the treatment of colorectal. The target is to develop an effective drug, which will help with inhibition of tumor growth and stopping the metastatic colorectal cancer (CRC).

Application for project co-funding within European Union, European Regional Development Fund:

  • Total project amount:  9,822,015.00 PLN
  • Co-funding portion:  6,873,131.75 PLN



European Funds - Smart Growth Republic of Poland NCBiR EU - Regional Development Fund

Tel: +1.343.291.1032

Global Headquarters
343 Preston Street
11th floor,
Ottawa, ON K1S 1N4

Room 5139, Level 5
159 Madang Road
North Block, Xintiandi
Shanghai, PR CHINA

Orion Biotechnology Poland SP. Z O.O.
Ul Bobrzyńskiego 14
30-348 Kraków POLAND

Campus Biotech Innovation Park
Avenue de Sécheron 15
1202 Genève

Contact Us

© 2018 Orion Biotechnology. All rights reserved.
Back to top